(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 15.5% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Neurocrine Biosciences's revenue in 2026 is $3,102,400,000.On average, 32 Wall Street analysts forecast NBIX's revenue for 2026 to be $375,654,736,488, with the lowest NBIX revenue forecast at $337,445,742,948, and the highest NBIX revenue forecast at $408,735,680,895. On average, 31 Wall Street analysts forecast NBIX's revenue for 2027 to be $431,359,427,070, with the lowest NBIX revenue forecast at $347,802,391,197, and the highest NBIX revenue forecast at $522,859,911,600.
In 2028, NBIX is forecast to generate $479,120,668,995 in revenue, with the lowest revenue forecast at $380,380,585,689 and the highest revenue forecast at $589,424,000,346.